Effects and safety of herbal medicines among community-dwelling residents during COVID-19 pandemic: A large prospective, randomized controlled trial (RCT).

Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China. BeijingKeyTech Statistical Consulting Co. Ltd, Beijing, China. Fudan University, Shanghai, China. University of Tennessee Health Science Center, Memphis, Tennessee, United States. Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China. Electronic address: tangjianyuan163@163.com. University of South Carolina College of Pharmacy, Columbia, South Carolina, United States. Electronic address: lu32@email.sc.edu. People's Liberation Army Air Force Military Medical University, Xi'an, China. Electronic address: xiajielai@fmmu.edu.cn. University of South Carolina College of Pharmacy, Columbia, South Carolina, United States. Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China. Electronic address: xcg718@aliyun.com. Chengdu University of Traditional Chinese Medicine, Chengdu, China. Electronic address: ysg28588@126.com.

Phytomedicine : international journal of phytotherapy and phytopharmacology. 2021;:153403

Abstract

BACKGROUND Since the declaration of COVID-19 as a global pandemic by the World Health Organization, countries are struggling with a shortage of medical capacities. It would be essential if the risk for preventable comorbidities, such as the common cold, can be reduced or prevented, so that the scarce medical resources and facilities can be focused on COVID-19. PURPOSE To evaluate the effects of two herbal medicines (Jinhaoartemisia antipyretic granules and Huoxiangzhengqi oral liquids) in reducing the risk of the common cold in community-dwelling residents in China during the COVID-19 outbreak. STUDY DESIGN A prospective open-label, parallel-group, cluster-randomized controlled trial (RCT), was conducted in Chengdu, China. METHODS A total of 22,065 participants from 11 communities were recruited during a period of one month. The trial started on 30 January and participants were followed up till 29 February 2020. Participants were randomly assigned to receive either a five-day herbal medicine therapy plus a reference manual or a reference manual only if they were allocated to the control group. The primary endpoint was the occurrence of patient-reported common cold symptoms. The secondary endpoint was the time in days from the receipt of herbal drugs/reference manual and the occurrence of the common cold symptoms. RESULTS Use of herbal medicine reduced the risk of the common cold by 89.6% (95% CI, 52.9% to 97.7%) in all community-dwelling residents, and by 94.0% (95% CI, 52.1% to 99.2%) in residents aged between 16 and 59 years old. Sensitivity analyses showed similar results. CONCLUSION This community-based RCT found that the use of a herbal medicine therapy (Jinhaoartemisia antipyretic granules and Huoxiangzhengqi oral liquids) could significantly reduce the risks of the common cold among community-dwelling residents, suggesting that herbal medicine may be a useful approach for public health intervention to minimize preventable morbidity during COVID-19 outbreak.

Methodological quality

Publication Type : Randomized Controlled Trial

Metadata